Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23197905 | 0.91 | KMT2A (0.43) | MAPTSMN1; SMN2DDX3X | |
| SCHEMBL23198166 | 0.87 | DDX3X (0.33) | MAPTFOLH1DGAT1DDX3X | |
| SCHEMBL23197899 | 0.77 | NPC1 (0.46) | MAPTSMN1; SMN2 | |
| SCHEMBL25791661 | 0.74 | P2RX7 (0.34) | MAPTSMN1; SMN2DGAT1 | |
| SCHEMBL24812536 | 0.73 | GLA (0.37) | SMN1; SMN2DGAT1 | |
| SCHEMBL22916917 | 0.71 | CYP19A1 (0.38) | DGAT1 | |
| SCHEMBL29325796 | 0.71 | FOLH1 (0.40) | SMN1; SMN2FOLH1DGAT1CA12CA1 | |
| SCHEMBL25791676 | 0.70 | CNR1 (0.39) | DGAT1 | |
| SCHEMBL23011671 | 0.69 | CYP19A1 (0.38) | FOLH1DGAT1 | |
| SCHEMBL27371572 | 0.68 | CYP19A1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101905-A1 | Development of Imaging and Therapeutic Glucose Analogues for Sodium Dependent Glucose Transporters | CASE WESTERN RESERVE UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101905-A1 | Development of Imaging and Therapeutic Glucose Analogues for Sodium Dependent Glucose Transporters | SLC5A1, SLC5A2, SLC2A1 | PTGS2 3953/4885GAA 367/4885MAPT 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.